The growth factor midkine regulates the renin-angiotensin system in mice

Journal of Clinical Investigation

Volumn 119, Issue 6, 2009, Pages 1616-1625

  Hobo, Akinori ^a   Yuzawa, Yukio ^a   Kosugi, Tomoki ^a   Kato, Noritoshi ^a   Asai, Naoto ^a   Sato, Waichi ^a   Maruyama, Shoichi ^a   Ito, Yasuhiko ^a   Kobori, Hiroyuki ^b   Ikematsu, Shinya ^c   Nishiyama, Akira ^d   Matsuo, Seiichi ^a   Kadomatsu, Kenji ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c OKINAWA NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

^d KAGAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GROWTH FACTOR; MIDKINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; HYPERTENSION; KIDNEY INJURY; KIDNEY MASS; LUNG PARENCHYMA; MOUSE; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BODY WEIGHT; CYTOKINES; FEMALE; KIDNEY; LUNG; MICE; MICE, KNOCKOUT; NEPHRECTOMY; NERVE GROWTH FACTORS; ORGAN SPECIFICITY; OXIDATIVE STRESS; PEPTIDYL-DIPEPTIDASE A; RENIN-ANGIOTENSIN SYSTEM;

EID: 67651007557     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI37249     Document Type: Article

References (60)

1. Atlas, S.A. 2007. The renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibition. J. Manag. Care Pharm. 13:9-20.
2. Kobori, H., Nangaku, M., Navar, L.G., and Nishiyama, A. 2007. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol. Rev. 59:251-287.
3. Ruster, C., and Wolf, G. 2006. Renin-angiotensin-aldosterone system and progression of renal disease. J. Am. Soc. Nephrol. 17:2985-2991.
4. Skeggs, L.T., Jr., Kahn, J.R., Lentz, K., and Shumway, N.P. 1957. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J. Exp. Med. 106:439-453.
5. Dzau, V.J. 1988. Tissue renin-angiotensin system: physiologic and pharmacologic implications. Introduction. Circulation. 77:I1-I3.
6. Sayed-Tabatabaei, F.A., Oostra, B.A., Isaacs, A., van Duijn, C.M., and Witteman, J.C. 2006. ACE polymorphisms. Circ. Res. 98:1123-1133.
7. Remuzzi, G., Perico, N., Macia, M., and Ruggenenti, P. 2005. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney Int. Suppl. S57-S65.
8. Kadomatsu, K., and Muramatsu, T. 2004. Midkine and pleiotrophin in neural development and cancer. Cancer Lett. 204:127-143.
9. Sato, W., et al. 2005. Midkine antisense oligodeoxyribonucleotide inhibits renal damage induced by ischemic reperfusion. Kidney Int. 67:1330-1339.
10. Kosugi, T., et al. 2006. Growth factor midkine is involved in the pathogenesis of diabetic nephropathy. Am. J. Pathol. 168:9-19.
11. Ezquerra, L., Herradon, G., Nguyen, T., Silos-Santiago, I., and Deuel, T.F. 2005. Midkine, a newly discovered regulator of the renin-angiotensin pathway in mouse aorta: significance of the pleiotrophin/midkine developmental gene family in angiotensin II signaling. Biochem. Biophys. Res. Commun. 333:636-643.
12. Werner, C., et al. 2008. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patient selection. Clin. Res. Cardiol. 97:418-431.
13. Wuhl, E., and Schaefer, F. 2008. Therapeutic strategies to slow chronic kidney disease progression. Pediatr. Nephrol. 23:705-716.
14. Ferrari, P. 2007. Prescribing angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in chronic kidney disease. Nephrology (Carlton). 12:81-89.
15. Olson, J.L., Hostetter, T.H., Rennke, H.G., Brenner, B.M., and Venkatachalam, M.A. 1982. Altered glomerular permselectivity and progressive sclerosis following extreme ablation of renal mass. Kidney Int. 22:112-126.
16. Hostetter, T.H., Olson, J.L., Rennke, H.G., Venkatachalam, M.A., and Brenner, B.M. 1981. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am. J. Physiol. 241:F85-F93.
17. Dikow, R., et al. 2004. Increased infarct size in uremic rats: reduced ischemia tolerance? J. Am. Soc. Nephrol. 15:1530-1536.
18. van Dokkum, R.P., et al. 2004. Myocardial infarction enhances progressive renal damage in an experimental model for cardio-renal interaction. J. Am. Soc. Nephrol. 15:3103-3110.
19. Pupilli, C., Chevalier, R.L., Carey, R.M., and Gomez, R.A. 1992. Distribution and content of renin and renin mRNA in remnant kidney of adult rat. Am. J. Physiol. 263:F731-F738.
20. Nishimura, M., Takahashi, H., and Yoshimura, M. 2007. Upregulation of the brain renin-angiotensin system in rats with chronic renal failure. Acta Physiol. (Oxf.). 189:369-377.
21. Riordan, J.F. 2003. Angiotensin-I-converting enzyme and its relatives. Genome Biol. 4:225.
22. Sato, W., et al. 2001. Midkine is involved in neutrophil infiltration into the tubulointerstitium in ischemic renal injury. J. Immunol. 167:3463-3469.
23. Narita, H., Chen, S., Komori, K., and Kadomatsu, K. 2008. Midkine is expressed by infiltrating macrophages in in-stent restenosis in hypercholesterolemic rabbits. J. Vasc. Surg. 47:1322-1329.
24. Inoh, K., Muramatsu, H., Ochiai, K., Torii, S., and Muramatsu, T. 2004. Midkine, a heparin-binding cytokine, plays key roles in intraperitoneal adhesions. Biochem. Biophys. Res. Commun. 317:108-113.
25. Villard, E., Alonso, A., Agrapart, M., Challah, M., and Soubrier, F. 1998. Induction of angiotensin I-converting enzyme transcription by a protein kinase C-dependent mechanism in human endothelial cells. J. Biol. Chem. 273:25191-25197.
26. Touyz, R.M. 2003. Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev. Cardiovasc. Ther. 1:91-106.
27. Vaziri, N.D., and Rodriguez-Iturbe, B. 2006. Mechanisms of disease: oxidative stress and inflammation in the pathogenesis of hypertension. Nat. Clin. Pract. Nephrol. 2:582-593.
28. Hoke, T.S., et al. 2007. Acute renal failure after bilateral nephrectomy is associated with cytokine-mediated pulmonary injury. J. Am. Soc. Nephrol. 18:155-164.
29. Kelly, K.J. 2003. Distant effects of experimental renal ischemia/reperfusion injury. J. Am. Soc. Nephrol. 14:1549-1558.
30. Anavekar, N.S., et al. 2004. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N. Engl. J. Med. 351:1285-1295.
31. Amann, K., Wanner, C., and Ritz, E. 2006. Crosstalk between the kidney and the cardiovascular system. J. Am. Soc. Nephrol. 17:2112-2119.
32. Kuczera, M., et al. 1991. Local angiotensin formation in hindlimbs of uremic hypertensive and renovascular hypertensive rats. J. Hypertens. 9:41-48.
33. Kidney Disease Outcomes Quality Initiative (K/DOQI). 2004. K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am. J. Kidney Dis. 43(5 Suppl. 1):S1-S290.
34. Iannone, A., Bini, A., Swartz, H.M., Tomasi, A., and Vannini, V. 1989. Metabolism in rat liver microsomes of the nitroxide spin probe tempol. Biochem. Pharmacol. 38:2581-2586.
35. Schnackenberg, C.G., and Wilcox, C.S. 1999. Two-week administration of tempol attenuates both hypertension and renal excretion of 8-Iso prostaglandin f2alpha. Hypertension. 33:424-428.
36. Johnson, F., and Giulivi, C. 2005. Superoxide dismutases and their impact upon human health. Mol. Aspects Med. 26:340-352.
37. Mollnau, H., et al. 2002. Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ. Res. 90:E58-E65.
38. Liao, T.D., et al. 2008. Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension. 52:256-263.
39. Kobori, H., Prieto-Carrasquero, M.C., Ozawa, Y., and Navar, L.G. 2004. AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. Hypertension. 43:1126-1132.
40. Graciano, M.L., et al. 2008. Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension. Am. J. Physiol. Renal Physiol. 294:F161-F169.
41. Horiba, M., et al. 2000. Neointima formation in a restenosis model is suppressed in midkine-deficient mice. J. Clin. Invest. 105:489-495.
42. Tu, X., et al. 2008. Anti-inflammatory renoprotective effect of clopidogrel and irbesartan in chronic renal injury. J. Am. Soc. Nephrol. 19:77-83.
43. Usui, H.K., et al. 2007. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 56:363-372.
44. Nakamura, E., et al. 1998. Disruption of the midkine gene (Mdk) resulted in altered expression of a calcium binding protein in the hippocampus of infant mice and their abnormal behaviour. Genes Cells. 3:811-822.
45. Sada, T., Koike, H., Nishino, H., and Oizumi, K. 1989. Chronic inhibition of angiotensin converting enzyme decreases Ca2+-dependent tone of aorta in hypertensive rats. Hypertension. 13:582-588.
46. Yoshida, K., Xu, H.L., Kawamura, T., Ji, L., and Kohzuki, M. 2002. Chronic angiotensin-converting enzyme inhibition and angiotensin II antagonism in rats with chronic renal failure. J. Cardiovasc. Pharmacol. 40:533-542.
47. Nishiyama, A., et al. 2004. Possible contributions of reactive oxygen species and mitogen-activated protein kinase to renal injury in aldosterone/salt-induced hypertensive rats. Hypertension. 43:841-848.
48. Ikematsu, S., et al. 2000. Serum midkine levels are increased in patients with various types of carcinomas. Br. J. Cancer. 83:701-706.
49. Muramatsu, H., and Muramatsu, T. 1991. Purification of recombinant midkine and examination of its biological activities: functional comparison of new heparin binding factors. Biochem. Biophys. Res. Commun. 177:652-658.
50. Murasugi, A., Kido, I., Kumai, H., and Asami, Y. 2003. Efficient production of recombinant human pleiotrophin in yeast, Pichia pastoris. Biosci. Biotechnol. Biochem. 67:2288-2290.
51. Pfeffer, J.M., Pfeffer, M.A., and Frohlich, E.D. 1971. Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rats. J. Lab. Clin. Med. 78:957-962.
52. Kohzuki, M., et al. 1995. Kinin and angiotensin II receptor antagonists in rats with chronic renal failure: chronic effects on cardio- and renoprotection of angiotensin converting enzyme inhibitors. J. Hypertens. 13:1785-1790.
53. Saito, T., et al. 1990. Progression of experimental focal glomerulosclerosis in the spontaneously hypertensive rat. J. Lab. Clin. Med. 115:165-173.
54. Raij, L., Azar, S., and Keane, W. 1984. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats. Kidney Int. 26:137-143.
55. Yuzawa, Y., et al. 1993. Antibody-mediated redistribution and shedding of endothelial antigens in the rabbit. J. Immunol. 150:5633-5646.
56. Shen, J., Ham, R.G., and Karmiol, S. 1995. Expression of adhesion molecules in cultured human pulmonary microvascular endothelial cells. Microvasc. Res. 50:360-372.
57. Nishiyama, A., Seth, D.M., and Navar, L.G. 2002. Renal interstitial fluid concentrations of angiotensins I and II in anesthetized rats. Hypertension. 39:129-134.
58. Kadomatsu, K., et al. 1997. Midkine induces the transformation of NIH3T3 cells. Br. J. Cancer. 75:354-359.
59. Kobori, H., Harrison-Bernard, L.M., and Navar, L.G. 2001. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J. Am. Soc. Nephrol. 12:431-439.
60. Livak, K.J., and Schmittgen, T.D. 2001. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 25:402-408.